What the trial was testing
The MG0002 enrolled 43 patients with myasthenia gravis. The study was sponsored by UCB Pharma and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a mid-stage trial — researchers are testing whether the treatment actually works for the condition. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Meaningful improvement in patients' ability to carry out daily activities — a result that helped support the drug's eventual FDA approval.
Neurology · 2021 · NCT03052751
These findings — that on the daily-activities endpoint (MG-ADL), showing meaningful improvement in swallowing, breathing, and daily function — were published in the Neurology and represent the headline result of the study.
Researchers tracked outcomes across 43 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with myasthenia gravis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Rozanolixizumab (Rystiggo) received FDA approval in 2023 for generalized myasthenia gravis in adults who are AChR or MuSK antibody positive. Ask your neurologist whether you qualify and whether Rystiggo or a similar FcRn inhibitor is appropriate for your situation.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open myasthenia gravis trials
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b * To evaluate the safety and preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.